Cloudstone reviews more than 300 companies for investment each year, as we have robust proprietary deal sourcing through direct and indirect relationships with entrepreneurs in unique medical, academic and technology groups such as Biodesign and Fogarty Institute –- “Talent flow is our deal flow.”

In addition to providing capital to our portfolio startup companies, Cloudstone offers advice and connections. Cloudstone assists our portfolio companies with FDA 510k compliance, follow-on financing, and strategic investment/partnering. We connect portfolio companies to various resources to help them grow.

Based on Healthtech trend and Cloudstone team’s complementary expertise, skills and relationships, Fund II will focus on 4 verticals:

Yong is a founding partner of Cloudstone Venture Fund. He is also the managing partner of Chongqing Vision Spring Innovation Fund (VSI, an RMB fund). He is currently on the board of Paragon Genomics, Wicue, GLF (IoT chip), and Honeycomb Data. He is also a Zenflow board observer. He has been an active venture investor since 2012. Prior to that, he was cofounder and angel investor in a few hightech companies in Silicon Valley and China, notable among them is the company that invented the USB drive in 1999, resulting in an IPO in Shenzhen.

Yong was the founder and former Chairman of Beijing SDR Consulting Group. At SDR, he led teams to provide systematic decision engagements on investments and management decisions to large technology enterprises such as China Mobile (300+ projects) and Guangdong Nuclear Power Group (100+ projects). He also provided investment decision advice on China market entry decisions for a few large Fortune 500 companies, notable projects include GM Shanghai Buick.

Yong worked at Strategic Decisions Group (SDG, later merged with, then bought back from Navigant Consulting) in Menlo Park, CA for more than a decade, from analyst to managing director for the Asia Pacific region. During this period, he led major investment decision-making projects for large pharmaceutical, energy, technology, finance and automobile companies in the US and globally.

Yong graduated from Stanford Engineering School with a PhD in Decision Analysis. He is an adjunct professor at the Shanghai Advanced Institute of Finance (SAIF) teaching the “Decision Analysis” course for MBA and MF students from financial institutions, hedge funds, PE funds and VCs.

Tom is a general partner of Cloudstone VC. He had been working with Yong and Mark closely on several Fund I portfolio company investments and joined Cloudstone in June 2019. He has been an active angel investor, serving on more than 20+ startups scientific and medical advisory boards -often as chair, and has a recent exit from Auris Health, Inc., which was acquired by Johnson & Johnson for approximately $3.4 billion in cash and earn-out.

Tom is the Emile Holman Professor and Chair Emeritus of the Stanford University School of Medicine Department of Surgery, as well as the Surgeon-in-Chief Emeritus at Lucile Packard Children’s Hospital, and the Co-Director of the Stanford Byers Center for BioDesign. Over the last 20 years, he has been a pioneer in the application of information technology to simulation-based surgical training and surgical robotics. For his work in this area and in surgical robotics, he has received two ComputerWorld Smithsonian Information Technology Innovation Awards. Tom has served in leadership positions in the American College of Surgeons, the American Surgical Association, and the American Board of Surgery.

Tom provides a unique access to well validated early stage founders/start ups in Silicon Valley through his roles at Stanford BioDesign and at the Fogarty Institute for Innovation, where he serves as Chairman of the Board of Directors. Tom serves and has served on numerous Boards of Directors and Scientific Advisory Boards of successful MedTech device start-ups, with 5 successful exits and more than 20 in the pipeline.

Tom graduated with a BS in Chemistry from the University of Wisconsin-Parkside, and earned his medical degree from the Medical College of Wisconsin. He has received numerous awards and honors for his teaching, research and leadership.

Mark Zhang is a founding partner of Cloudstone Venture Fund. Mark holds board seats in Cloudstone’s portfolio companies, including Eclipse and Galatech.

He is a high-tech veteran with more than 30 years of experience as senior executive and investor. He had participated in and successfully created several Silicon Valley high-tech start-ups and exits. He was previously an angel investor and invested in various tech start-ups. He has rich project resources and extensive networks in venture capital.

Mark specializes in healthcare related fields such as: biotechnology, pharmaceuticals, medical equipment and high-tech intelligent manufacturing. He is the cofounder of Echo lab, a biotech incubator in Bay area. He also serves as the chairman of SV1898, a multi-domain business incubation platform established by nearly 100 Peking University alumni in Silicon Valley.

Mark has a deep understanding of the trend of high-tech fields. He previously worked at three Fortune 500 companies, led the development of several blockbuster products. Mark has professional experience in assessing the feasibility of industrial product conversion in laboratory results, designing products, operating, R&D, and bringing products to market.

Mark graduated from Peking University with B.S. in chemistry and then obtained his Ph.D. in biophysical chemistry from Michigan State University.

Alexa Joined Cloudstone as a Partner in 2020. She has private investment experience in venture, fixed income and hedge fund investing and as an angel/private investor. Alexa served as Vice Chair of Avalence LLC, a clean energy company; co-manager of TriCapital Ltd., a Bermuda based investment company; and on the Investment Risk and Advisory Committee of Dunbar Capital, a hedge fund of funds.

Prior to Cloudstone, Alexa was founder and partner of Glade Arch Partners a merchant banking firm providing financial and strategic advisory and mergers & acquisitions advisory services for health and wellness companies from Series A to middle market businesses. She provided strategic advisory to a rapidly growing Skeletal Strength conditioning company, and advised private equity on an investment in Digital Health

Prior to that, Alexa founded and was CEO of Mille Capital, a mid market private equity and mergers & acquisitions advisory firm. She advised clients in healthcare, travel and information technology industries on mergers & acquisitions, capital raising and fairness opinions. Many assignments were global, or across continents. Prior to that, Alexa was a senior banker with Kidder Peabody, and Drexel Burnham Lambert where she completed numerous private equity transactions, IPOs and other assignments with clients from entrepreneurs to Fortune 500s.

Alexa graduated from Stanford Graduate School of Business with and MBA in Finance, and from Harvard with a BA in Economic Development.